MONTE ROSA THERAPEUTICS INC's ticker is GLUE and the CUSIP is 61225M102. A total of 76 filers reported holding MONTE ROSA THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,826,748 | -45.7% | 2,360,093 | +2.3% | 0.00% | – |
| Q1 2024 | $16,264,413 | +21.4% | 2,307,009 | -2.7% | 0.00% | – |
| Q4 2023 | $13,401,687 | -24.3% | 2,371,980 | -35.8% | 0.00% | -100.0% |
| Q3 2023 | $17,697,460 | -33.1% | 3,694,668 | -4.3% | 0.00% | 0.0% |
| Q2 2023 | $26,443,438 | -6.0% | 3,860,356 | +7.0% | 0.00% | 0.0% |
| Q1 2023 | $28,117,389 | +2.7% | 3,609,421 | +0.3% | 0.00% | 0.0% |
| Q4 2022 | $27,384,859 | -3.4% | 3,598,536 | +3.7% | 0.00% | 0.0% |
| Q3 2022 | $28,352,000 | -11.5% | 3,470,232 | +4.8% | 0.00% | 0.0% |
| Q2 2022 | $32,033,000 | -27.0% | 3,312,569 | +5.9% | 0.00% | 0.0% |
| Q1 2022 | $43,861,000 | -8.7% | 3,128,392 | +32.9% | 0.00% | 0.0% |
| Q4 2021 | $48,063,000 | +4.3% | 2,353,764 | +13.8% | 0.00% | 0.0% |
| Q3 2021 | $46,091,000 | +31.0% | 2,068,677 | +33.5% | 0.00% | 0.0% |
| Q2 2021 | $35,183,000 | – | 1,549,885 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,472,331 | $20,642,000 | 11.14% |
| Cormorant Asset Management, LP | 3,002,199 | $42,091,000 | 3.23% |
| NEA Management Company, LLC | 7,703,205 | $107,999,000 | 3.12% |
| Avoro Capital Advisors LLC | 3,311,434 | $46,426,000 | 0.85% |
| Alphabet Inc. | 1,464,015 | $20,525,000 | 0.67% |
| Casdin Capital, LLC | 960,882 | $13,472,000 | 0.60% |
| RTW INVESTMENTS, LP | 1,214,572 | $17,028,000 | 0.35% |
| Woodline Partners LP | 48,100 | $674,000 | 0.01% |
| FMR LLC | 6,994,548 | $98,064,000 | 0.01% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5,350,923 | $75,020,000 | 0.01% |